OMER
$11.21+0.07 (+0.63%)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narso...
Recent News
Omeros Corporation's (NASDAQ:OMER) market cap dropped US$60m last week; individual investors who hold 50% were hit as were institutions
Key Insights The considerable ownership by individual investors in Omeros indicates that they collectively have a...
Exchange-Traded Funds, Equity Futures Higher Ahead of First Trading Day of 2026
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.6%, and the actively tra
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.
Omeros (OMER): Revisiting Valuation After a Powerful Multi‑Year Share Price Repricing
Omeros (OMER) has quietly turned heads with a powerful move in its share price recently, and the shift looks tied less to headlines and more to how investors are rethinking its pipeline. See our latest analysis for Omeros. After a volatile stretch, Omeros shares have surged to around $15.36, with a 90 day share price return of 250.68 percent and a standout three year total shareholder return of 550.85 percent. This signals powerful, momentum driven repricing of its risk and growth story. If...
Why Omeros (OMER) Is Up 74.0% After First-In-Class TA-TMA Drug Wins FDA Approval
Earlier this month, Omeros Corporation announced that the FDA approved YARTEMLEA (narsoplimab-wuug), the first and only therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children aged two and older, with a U.S. launch planned for January 2026 and an EMA decision expected mid-2026. This approval not only moves Omeros from a development-stage to a commercial-stage company but also positions YARTEMLEA as a first-mover treatment in a...